Factbox-Companies in Alzheimer's race after US nod for Eisai/Biogen drug
Views: 2192
2023-07-08 02:21
Eisai Co Ltd and Biogen Inc's Leqembi emerged as the first Alzheimer's treatment to win the U.S. Food

Eisai Co Ltd and Biogen Inc's Leqembi emerged as the first Alzheimer's treatment to win the U.S. Food and Drug Administration's standard approval on Thursday, a milestone in drug development for a disease that has seen multiple failures in the past.

The following is a list of companies that are currently developing treatments that aim to modify the memory-robbing disease:

Company Drug or Stage of Mechanism

Therapy development &

indication

Eli Lilly donanemab Designed to

and Co Late-stage trial target toxic

for early protein plaque

Alzheimer’s in the brain

known as

beta-amyloid

and remove

brain plaques

to slow

cognitive

decline

BioVie Inc NE3107 An oral small

Late-stage trial molecule that

for mild to aims to inhibit

moderate neuroinflammati

Alzheimer’s on and insulin

resistance

AB Science masitinib An oral

SA Late-stage study tyrosine kinase

for inhibitor that

mild-to-moderate targets immune

Alzheimer’s cells

responsible for

neuroinflammati

on

Annovis buntanetap An

Bio Inc Mid-to-late-stage orally-administ

trial for moderate ered small

Alzheimer's molecule

inhibitor of

several

neurotoxic

proteins

Cognition CT1812 Oral drug

Therapeuti Mid-stage trial designed to

cs Inc for bind to a

mild-to-moderate specific

Alzheimer’s receptor in

brain cells,

which mediates

the attachment

of beta-amyloid

Coya COYA 301 Designed to

Therapeuti Mid-stage trial inhibit

cs Inc for molecules

mild-to-moderate responsible for

Alzheimer’s neuroinflammati

on and improve

cognitive

function

Actinogen xanamem Blocks

Medical Mid-stage trial production of a

Limited for mild-moderate hormone linked

Alzheimer's to stress

called cortisol

inside brain

cells and is

associated with

cognitive

impairment

AC Immune ACI-24.060 Early- An

SA -to-mid stage antibody-based

trial for immunotherapy

Alzheimer’s vaccine

designed to

target beta

amyloid plaques

Biogen Inc BIIB080 An antisense

Mid-stage trial oligonucleotide

for early-stage therapy

Alzheimer’s directed

against "tau"

proteins

Longeveron lomecel-B A cell therapy

Inc Mid-stage trial designed to

for mild stimulate

Alzheimer’s neuroregenerati

on and prevent

disease

progression

(Reporting by Pratik Jain and Mariam Sunny in Bengaluru; Editing by Maju Samuel)

Tags eisai epus news companies alzheimers biogen